DHR vs TKNO
DHR: A premier global life sciences and diagnostics innovator that applies the Danaher Business System to accelerate scientific discovery and improve patient outcomes. TKNO: Teknova provides custom, high-quality, and scalable reagents essential for the discovery and commercialization of next-generation therapies, vaccines, and diagnostics.
Side-by-side fundamentals
| Metric | DHR | TKNO | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $233.86 | $5.85 | |
| Market cap | $164.4B | $314M | |
| P/E as of 2026-10-21 | 41.54 | n/a | |
| Net margin FY2025, SEC XBRL | +14.7% | -42.6% | DHR higher |
| Gross margin FY2025, SEC XBRL | +59.1% | +33.2% | DHR higher |
| Operating margin FY2025, SEC XBRL | +19.1% | -41.9% | DHR higher |
| ROE FY2025, SEC XBRL | +6.9% | -25.1% | DHR higher |
| ROA FY2025, SEC XBRL | +4.3% | -16.7% | DHR higher |
| Debt / equity | 0.51 | 0.21 | TKNO lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +2.9% | +7.3% | TKNO higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -0.7% | TKNO higher |
| Dividend yield as of 2026-09-03 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.78 | 1.77 | |
| 1-year return as of 2026-10-21 close | +5.9% | +4.1% | DHR higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.